Targeting a signaling pathway activated by acidic tumor environment restores treatment response to PARP inhibitors in ovarian cancer
PARP inhibitors are among the most widely used therapies for ovarian cancer, but their long-term effectiveness is limited by acquired resistance
Researchers found a signaling pathway activated by the tumor microenvironment was a major driver of resistance, and blocking the pathway was able to resensitize tumors
The pathway was activated because the tumor microenvironment is acidic, which is common in several tumor...
Epigenetic therapy shows promise against treatment-resistant AML
Next-generation epigenetic therapy showed stronger anti-leukemia activity than current standard treatments in preclinical models of acute...
Fasting primes gut microbiome to improve intestinal recovery after radiation treatment
Researchers identified a gut bacterium that helps prime intestinal stem cells for faster recovery
In preclinical models, short-term...
Biomarker-guided drug combinations may improve outcomes in treatment-resistant melanoma
In a preclinical study, adding a BCL2 inhibitor to standard melanoma therapy shrank tumors that had stopped responding to therapy
The study identified two proteins, BCL2 and MCL1, that may serve as predictive biomarkers for matching patients to specific drug combinations
Results also suggest that BRAF-MEK inhibitors may reduce heart-related side effects of MCL1 inhibitors, which have previously limited their clinical potential
The findings...
Study identifies a new cause of age-related inflammation, suggesting promising treatment pathway
As cells age, they increasingly export nucleic acid structures called R-loops from the nucleus, triggering an immune response that causes...